Angelini Pharma secures exclusive option to license global development and commercialization rights for SVG1051, a pre-clinical investigational novel compound with broad potential to treat brain ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

or more than 100 years, the billionaire Angelini family had been content to run a largely European business empire from their headquarters in Rome: pharmaceuticals like the Italian equivalent of ...

- The collaboration agreement combines Angelini Pharma’s expertise in neurological diseases with JCR Pharmaceuticals’ scientific and technological excellence to deliver biotherapeutics across the ...

Angelini Pharma announced a definitive agreement to acquire Catalyst Pharmaceuticals in an all-cash transaction valued at approximately $4.1 billion. Under the agreement, Catalyst shareholders will ...

Angelini Ventures joins top-tier investor syndicate Investment will fund Phase 1b studies evaluating Therini Bio's lead candidate, THN391, for the treatment of Alzheimer's Disease (AD) and Diabetic ...

Angelini Pharma has signed a definitive agreement to purchase Catalyst Pharmaceuticals for a total equity value of nearly €3.5bn ($4.1bn), marking its entrance into the US market and consolidating its ...

PRINCETON, N.J., Aug. 10 /PRNewswire/ -- Angelini Labopharm today announced that OLEPTRO™ (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant ...

Investment supports the development of first-in-class, non-addictive, non-hallucinogenic molecules with a non-synaptic target, differentiated from existing drugs First start-up company from Argobio's ...

ROME, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Angelini Pharma, part of the privately owned Angelini Industries, and Sovargen, a South-Korean biotechnology company, announced today that they signed an ...